ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL kinase activity that was comparable to that of normal stem/progenitor counterparts.